Literature DB >> 20826651

Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays.

Carrie Dykes1, Hulin Wu, Matthew Sims, Jeanne Holden-Wiltse, Lisa M Demeter.   

Abstract

The replication fitness of HIV-1 drug-resistant mutants has been measured using either multiple-cycle or single-cycle assays (MCAs or SCAs); these assays have not been systematically compared. We developed an MCA and an SCA that utilized either intact or env-deleted recombinant viral vectors, respectively, in which virus-infected cells were detected by flow cytometry of a reporter gene product. Fitness was measured using each assay for 11 protease mutants, 9 reverse transcriptase mutants, and two mutants with mutations in gag p6, which is important for the release of virus particles from the cell membrane. In the SCA, fitness (replication capacity [RC]) was defined as the proportion of cells infected by the mutant compared to the wild type 40 h after infection. MCA fitness (1+s) was determined by comparing the changes in the relative proportions of cells infected by the mutant and the wild type between 3 and 5 days after infection. Five protease mutants showed statistically different fitness values by the MCA versus the SCA: the D30N, G48V, I50V, I54L, and I54M mutants. When all the mutants were ranked in order from most to least fit for both assays, 4 protease mutants moved more than 5 positions in rank: the D30N, I54L, I54M, and V82A mutants. There were no significant differences in fitness for the gag p6 or reverse transcriptase mutants. We propose that discordant results in the MCA and SCA are due to alterations in late events in the virus life cycle that are not captured in an SCA, such as burst size, cell-to-cell transmission, or infected-cell life span.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826651      PMCID: PMC3020834          DOI: 10.1128/JCM.00605-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  51 in total

1.  Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.

Authors:  C Aiken
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations.

Authors:  Jérôme Deval; Kirsten L White; Michael D Miller; Neil T Parkin; Jérôme Courcambeck; Philippe Halfon; Boulbaba Selmi; Joëlle Boretto; Bruno Canard
Journal:  J Biol Chem       Date:  2003-10-09       Impact factor: 5.157

3.  Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.

Authors:  Carrie Dykes; Jiong Wang; Xia Jin; Vicente Planelles; Dong Sung An; Amanda Tallo; Yangxin Huang; Hulin Wu; Lisa M Demeter
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

4.  Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.

Authors:  C Dykes; K Fox; A Lloyd; M Chiulli; E Morse; L M Demeter
Journal:  Virology       Date:  2001-07-05       Impact factor: 3.616

5.  Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles.

Authors:  J Reiser; G Harmison; S Kluepfel-Stahl; R O Brady; S Karlsson; M Schubert
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

6.  The HIV-TSG101 interface: recent advances in a budding field.

Authors:  Eric O Freed
Journal:  Trends Microbiol       Date:  2003-02       Impact factor: 17.079

7.  Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

Authors:  Jing Lu; Prakash Sista; Françoise Giguel; Michael Greenberg; Daniel R Kuritzkes
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure.

Authors:  Andrea De Luca; Jodi Weidler; Simona Di Giambenedetto; Eoin Coakley; Antonella Cingolani; Michael Bates; Yolanda Lie; Rick Pesano; Roberto Cauda; Jonathan Schapiro
Journal:  J Acquir Immune Defic Syndr       Date:  2007-08-01       Impact factor: 3.731

9.  Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection.

Authors:  Jason D Barbour; Frederick M Hecht; Terri Wrin; Mark R Segal; Clarissa A Ramstead; Teri J Liegler; Michael P Busch; Christos J Petropoulos; Nicholas S Hellmann; James O Kahn; Robert M Grant
Journal:  J Infect Dis       Date:  2004-06-18       Impact factor: 5.226

Review 10.  Clinical significance of human immunodeficiency virus type 1 replication fitness.

Authors:  Carrie Dykes; Lisa M Demeter
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

View more
  5 in total

1.  Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.

Authors:  Jiong Wang; Gang Zhang; Robert A Bambara; Dongge Li; Hua Liang; Hulin Wu; Hannah M Smith; Nicholas R Lowe; Lisa M Demeter; Carrie Dykes
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

2.  HIV-1 infection renders brain vascular pericytes susceptible to the extracellular glutamate.

Authors:  Dorota Piekna-Przybylska; Kavyasri Nagumotu; Danielle M Reid; Sanjay B Maggirwar
Journal:  J Neurovirol       Date:  2018-11-06       Impact factor: 2.643

3.  Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.

Authors:  Jan Weber; Ana C Vazquez; Dane Winner; Justine D Rose; Doug Wylie; Ariel M Rhea; Kenneth Henry; Jennifer Pappas; Alison Wright; Nizar Mohamed; Richard Gibson; Benigno Rodriguez; Vicente Soriano; Kevin King; Eric J Arts; Paul D Olivo; Miguel E Quiñones-Mateu
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

4.  Monocytes complexed to platelets differentiate into functionally deficient dendritic cells.

Authors:  Meera V Singh; Sumanun Suwunnakorn; Sydney R Simpson; Emily A Weber; Vir B Singh; Pawel Kalinski; Sanjay B Maggirwar
Journal:  J Leukoc Biol       Date:  2020-07-14       Impact factor: 4.962

5.  Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome.

Authors:  Hongshuo Song; Jeffrey W Pavlicek; Fangping Cai; Tanmoy Bhattacharya; Hui Li; Shilpa S Iyer; Katharine J Bar; Julie M Decker; Nilu Goonetilleke; Michael K P Liu; Anna Berg; Bhavna Hora; Mark S Drinker; Josh Eudailey; Joy Pickeral; M Anthony Moody; Guido Ferrari; Andrew McMichael; Alan S Perelson; George M Shaw; Beatrice H Hahn; Barton F Haynes; Feng Gao
Journal:  Retrovirology       Date:  2012-10-30       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.